Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3058-3063

  Chang, Jenny ^a   Powles, T J ^a   Allred, D C ^a   Ashley, S E ^a   Clark, G M ^a   Makris, A ^a   Assersohn, L ^a   Gregory, R K ^a   Osborne, C K ^a   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0032887665     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3058     Document Type: Article

References (30)

1. Early Breast Cancer Trialist Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
2. Allegra JC, Lippman ME, Thompson EB, et al: Estrogen receptor status: An important variable in predicting response to endocrine therapy in advanced breast cancer. Eur J Cancer 16:323-331, 1980
3. Mouridsen H, Palshof T, Patterson L, et al: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131-141, 1978
4. Gasparini G BM, Doglioni C, Palma PL, et al: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
5. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
6. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
7. Elledge RM, Gray R, Mansour E, et al: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisolone for breast cancer. J Natl Cancer Inst 87:1254-1256, 1995
8. Clark GM, Dressier LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
9. Makris A, Powles TJ, Dowsett M, et al: Changes in proliferation in primary breast cancers during chemoendocrine therapy. Eur J Cancer 31A:653, 1995 (abstr) (suppl)
10. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
11. Allred DC HJ, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mol Path 11:155-168, 1998
12. Dressler LG, Seamer LC, Owens MA, et al: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61:420-427, 1988
13. Calais G, Berger C, Descamps P, et al: Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast cancer larger than 3 cm. Cancer 74:1283-1288, 1994
14. Scholl SM, Pierga JY, Asselain B, et al: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969-1975, 1996
15. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
16. O'Reilly SM, Camplejohn RS, Rubens RD, et al: DNA flow cytometry and response to preoperative chemotherapy from primary breast cancer. Eur J Cancer 28:681-683, 1992
17. Remvikos Y, Vielh P, Padoy E, et al: Breast cancer proliferation measured on cytological samples: A study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer 64:501-507, 1991
18. Spyratos F, Brifford M, Tubiana-Hulin M, et al: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma: II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up. Cancer 69:470-475, 1992
19. Chevillard S, Lebeau J, Fouillart P, et al: Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-Phase Fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471-2478, 1997
20. Chevillard S, Poillart P, Beldjord C, et al: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292-300, 1996
21. Rasbridge SA, Gillet CE, Seymour A-M, et al: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70:335-341, 1994
22. Billgren A-M, Rutqvist LE, Skoog L, et al: Changes of proliferating fraction during neoadjuvant chemotherapy of primary breast cancer as a predictor of objective response. Breast Cancer Res Treat 32:63, 1994 (abstr) (suppl)
23. Gerdes J, Lempke H, Baisch H, et al: Production of a mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983
24. Kamel OW, Franklin WA, Ringus JC, et al: Thymidine labelling index and Ki67 growth fraction in lesions of the breast. Am J Path 134:107-113, 1989
25. American Society of Clinical Oncology: 1997 update of recommendations for use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793-795, 1997
26. Kiang DT, Frenning DH, Goldman AI, et al: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330-1334, 1978
27. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
28. Bianco AR, Laurentiis C, Carlomango R, et al: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 373)
29. Elledge RM, Green S, Ciocca D, et al: HER-2 expression and response to tamoxifen in estrogen-receptor positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res 4:7-12, 1998
30. Mamounas EP: NSABP Protocol B-27: Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology 11:37-40, 1997